Novartis Ag (NVS) Common Equity (2009 - 2025)

Novartis Ag (NVS) has 13 years of Common Equity data on file, last reported at $46.5 billion in Q4 2025.

• Quarterly Common Equity rose 5.68% year-over-year to $46.5 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $46.5 billion (up 5.68% YoY) and the FY2025 annual result came in at $46.5 billion, up 5.68% from the prior year.
• Common Equity grew to $46.5 billion in Q4 2025 per NVS's latest filing, from $42.1 billion in the prior quarter.
• The five-year high for Common Equity was $67.8 billion in Q4 2021, with the low at $41.9 billion in Q2 2024.
• Average Common Equity over 5 years is $51.8 billion, with a median of $49.3 billion recorded in 2023.
• Year-over-year, Common Equity soared 4879.56% in 2021 and dropped 21.33% in 2023.
• Novartis Ag's Common Equity stood at $67.8 billion in 2021, then dropped by 12.38% to $59.4 billion in 2022, then decreased by 21.33% to $46.8 billion in 2023, then slipped by 5.78% to $44.0 billion in 2024, then climbed by 5.68% to $46.5 billion in 2025.
• Business Quant data shows NVS's Common Equity at $46.5 billion in Q4 2025, $42.1 billion in Q2 2025, and $44.0 billion in Q4 2024.